
The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
The FDA has taken a clear position with Project Optimus in shifting toward more progressive tailored approaches while rejecting antiquated study designs to evolve clinical trial strategies to better align with newer drug classes.
Published: February 13th 2025 | Updated: March 4th 2025
Published: February 19th 2025 | Updated: February 26th 2025
Published: March 24th 2023 | Updated:
Published: April 28th 2021 | Updated:
Published: July 26th 2024 | Updated:
Published: January 31st 2024 | Updated: